Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Phase 1 N=27 Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
Pancreatic Carcinoma Non-resectable · Metastatic Pancreatic Cancer
Primary: To Determine the Dose Limiting Toxicities — 27 participants
Phase 3 N=129 Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=75 Priming Immunotherapy in Advanced Disease With Radiation
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Phase 2 N=3 Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
N/A N=256 Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: 3-year Overall Survival Rate — 67.9; 68.4 percentage of participants — p=0.32
Phase 2 N=11 Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma · Stage I Pancreatic Cancer
Primary: Number of Participants With Progressive Disease, — 2 Participants
Phase 2 N=18 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=51 Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
Pancreatic Cancer
Primary: One Year Survival Rate — 0.502 proportion of patients
Phase 2 N=117 Navelbine And Radiotherapy in Locally Advanced Lung Cancer
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
N/A N=39 Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
Cancer
Primary: Pain — 0; 0; 0; 0 units on a scale
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=10 Locally Advanced NSCLC Hyperfractionated RT
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Phase 2 N=19 Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Participants With Radiographic Objective Response (OR) — 0 participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Phase 2 N=37 Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms, Male · Carcinoma, Ductal
Primary: Overall Tumor Response — 1; 8; 14; 9 participants
Phase 2 N=160 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
Breast Cancer
Primary: Progression Free Survival — 103; 81 Days
Phase 1 N=20 GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Phase 2 N=52 Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
Metastatic Breast Cancer · Locally Advanced Breast Cancer
Primary: Progression Free Survival (PFS) Time — 4.80 months
Phase 3 N=564 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Phase 2 N=46 Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage III Pancreatic Cancer
Primary: Overall Survival (OS) — 7.3 months
Phase 2 N=57 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Response — 7; 6; 12; 15 participants